AGEN
Agenus Inc
$3.25
-0.25 (-7.14%)
At close · Jul 8
Market Cap
$135.75M
Shares
41,642,431
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.25
Open$3.45
Day$3.25–3.63
52W$2.71–7.34
Avg vol 30d798K
Short int4.8M · 11.5% float · 8.3d
Short vol71%
Last earningsMay 11, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 11
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−11%
below
Price vs 50-day avg
−4%
below
RSI (14)
50
neutral
MACD trend
Positive
52-week position
12%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+4%
trailing
6-month return
−30%
trailing
YTD return
+4%
this year
Relative strength
−37%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Flat
2 of 86 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
11.47% of float · ▼ -12.6% MoM · 8.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
86 holders — mid 2-yr range
Squeeze score
77
high risk · 0–100
Fundamentals
Revenue growth
+90%
Y/Y
EPS growth
+100%
Y/Y
Free cash flow
$-77.2M
Valuation
P/E 1.6
below peers
Balance sheet
$41.7M
net debt
Quant / Vol
risk profile
Volatility
84%
annualized · 1-yr
Max drawdown
−61%
past year
ATR
7.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 22, 2026
Est · unconfirmed
· in 6 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−11%
Bearish
Price vs 50-day avg
−4%
Neutral
RSI (14)
50
Neutral
MACD trend
Positive
Bullish
52-week position
12%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Flat
2 of 86 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
11.47% of float · ▼ -12.6% MoM · 8.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
86 holders — mid 2-yr range
Price context
position in its 52-week range
52-wk low $3
Now $3 · 12%
52-wk high $7
vs 200-day avg -11%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AGEN
this stock
Agenus Inc
|
$135.75M | +3.5% | +89.9% | 1.6 | 11.5% |
|
ONC
BeOne Medicines Ltd.
|
$436.30B | -0.6% | +22179.2% | 887.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AGEN | +6.2% | +3.5% | -29.5% | +6.2% | +3.5% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +6.4% | +2.7% | -36.9% | +6.4% | -5.8% |